NEW YORK (Genomeweb) – ArcherDx announced on Monday an agreement to develop and commercialize a next generation sequencing-based companion diagnostic for Celgene's investigational drug CC-122 for diffuse large B cell lymphoma.
As part of the deal, ArcherDx will use its Anchored Multiplex PCR technology in combination with the Illumina MiSeqDx sequencer and Archer Analysis bioinformatics software to develop the companion diagnostic. The test will be based on a proprietary gene expression signature developed by Celgene to identify patients most likely to respond to CC-122, a cereblon-modulating agent being investigated in multiple disease settings.
Boulder, Colorado-based ArcherDx will retain the global rights to commercialize the test and will pursue all filings with regional regulators, it said. Additional terms of the deal were not disclosed.